US 12,329,784 B2
Gut microbiota and treatment of cancer
Yan Li, La Jolla, CA (US); Scott Peterson, La Jolla, CA (US); Linda Bradley, La Jolla, CA (US); Roberto Tinoco, La Jolla, CA (US); Ze'ev Ronai, San Diego, CA (US); and Shiri Ashkenazi, Haifa (IL)
Assigned to Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US); and Technion Research & Development Foundation Ltd., Haifa (IL)
Filed by Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US); and Technion Research & Development Foundation Ltd., Haifa (IL)
Filed on Jan. 30, 2023, as Appl. No. 18/103,166.
Application 18/103,166 is a continuation of application No. 16/461,850, granted, now 11,571,446, previously published as PCT/US2017/062257, filed on Nov. 17, 2017.
Claims priority of provisional application 62/436,206, filed on Dec. 19, 2016.
Claims priority of provisional application 62/424,237, filed on Nov. 18, 2016.
Prior Publication US 2023/0270795 A1, Aug. 31, 2023
Int. Cl. A61K 35/74 (2015.01); A61K 31/7004 (2006.01); A61K 31/7008 (2006.01); A61K 31/7024 (2006.01); A61K 31/733 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 35/74 (2013.01) [A61K 31/7004 (2013.01); A61K 31/7008 (2013.01); A61K 31/7024 (2013.01); A61K 31/733 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01)] 15 Claims
 
1. A method of treating colon cancer or melanoma in a human subject in need thereof, the method comprising administering to the human subject a composition comprising a therapeutically effective amount of one or more bacteria selected from the group consisting of
Bacteroides acidifaciens, Bacteroides xylanisolvens, Parabacteroides merdae, and Flavobacterium; and
administering one or more anti-cancer agents, wherein the one or more anti-cancer agents comprises a Serine/threonine-protein kinase B-raf (BRAF) inhibitor or a Mitogen-activated protein kinase kinase (MEK) inhibitor.